Advertisement
Neonates born to mothers exposed to β-blockers at the time of delivery have increased risk of neonatal hypoglycemia and bradycardia

Hypoglycemia, Bradycardia Up in Neonates Exposed to β-Blockers

0
Increased risk for neonates born to exposed mothers, even after adjustment for confounders
Levetiracetam or topiramate use during pregnancy doesn't appear to harm the child's future cognitive abilities

Levetiracetam, Topiramate May Be Safer During Pregnancy

0
Small study finds two drugs don't harm a child's cognitive abilities, but valproate can
Fourteen genes have been identified that may help determine whether a cancer treatment could help a patient

Biomarker Score May Help Predict Response to Cancer Treatment

0
Researchers say finding might help identify patients most likely to be helped by chemotherapy, radiation
A new biological drug to treat rheumatoid arthritis and other inflammatory diseases has been approved by the U.S. Food and Drug Administration.

FDA Approves Biosimilar Drug Erelzi for Rheumatoid Arthritis

0
Erelzi is a biosimilar for Enbrel; treats RA and other inflammatory diseases
For patients with peripheral arterial disease

Ischemic Events Down With Prolonged DAPT in PAD

0
Lower risk of ischemic events seen for patients with peripheral arterial disease undergoing PCI
Retinoic acid might have a role in suppressing colorectal cancer

Retinoic Acid May Help Prevent, Treat Colorectal Cancer

0
Researchers are studying connection between retinoic acid and inflammation in gut
Though a growing number of Americans are able to afford prescription medications

ACA Is Helping More Americans Afford Prescriptions

0
Improvement seen in all age levels, but millions still struggle with the cost of prescription drugs
For patients with type 2 diabetes and coronary artery disease

CABG Plus Optimal Medical Therapy Best in T2DM and CAD

0
During long-term follow-up, CABG + OMT linked to reduction in composite of death, MI, stroke
For patients with heart failure with reduced ejection fraction

Sacubitril-Valsartan Reasonably Cost-Effective in Heart Failure

0
Cost of $47,053 per quality-adjusted life-year gained in base-case analysis
For acute major bleeding within 18 hours after factor Xa inhibitor administration

Andexanet Bolus, Infusion Cuts Anti-Factor Xa Activity

0
Findings in patients with acute major bleeding associated with factor Xa inhibitors